Vertex Pharmaceuticals Stock: A Deep Dive Into Analyst ... - Nasdaq

3 days ago · The perception of Vertex Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, …

CouponFollow Extension

$113
OFF

Vertex Pharmaceuticals' SWOT Analysis: Stock Poised For Growth

3 weeks from now

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company with a market capitalization of $113.7 billion, is navigating a critical juncture as it seeks to expand its …

msn.com

$10
OFF

Vertex Pharmaceuticals' Next Big Chapter? Vertex Stock Surges On ...

3 weeks from now

2 days ago · Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex stock jumped.

investors.com

$520.00
OFF

Vertex Pharmaceuticals: Strategic Advancements And Promising …

3 weeks from now

Jan 14, 2025 · Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of $520.00. Discover …

businessinsider.com

$545
OFF

Vertex Pharmaceuticals Price Target Raised To $545 From $520 At …

3 weeks from now

2 days ago · BMO Capital analyst Evan Seigerman raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $545 from $520 and keeps an Outperform rating on the shares.

businessinsider.com

$415
OFF

Metsera, Maze Secure Combined $415 Million In IPOs - BioPharma …

3 weeks from now

3 days ago · Metsera and Maze Therapeutics are the second and third biotechnology firms this year to go public, raising $275 million and $140 million, respectively, in a pair of new stock …

biopharmadive.com

$28.66
OFF

Teva Pharmaceutical Indus Options Trading: A Deep Dive Into

3 weeks from now

3 days ago · A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $28.666666666666668. Turn $1000 into $1270 in just …

nasdaq.com

FAQs about Vertex Pharmaceuticals Stock: A Deep Dive Into Analyst ... - Nasdaq Coupon?

How do analysts evaluate Vertex Pharmaceuticals (vertex) stock?

Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Vertex Pharmaceuticals compared to the broader market. Price Targets: Analysts set price targets as an estimate of a stock's future value. ...

Is Vertex Pharmaceuticals a good stock to buy in 2025?

Vertex Pharmaceuticals continues to execute its commercialization of three new drugs, JOURNAVX, CASGEVY, and ALYFTREK. Two of which have been approved by the FDA since December. Vertex's valuation appears high due to recent expenses, but analysts expect substantial earnings growth in 2025 as acquisition and clinical expenses subside. ...

Is vertex a good stock to buy?

Recent analyst reports and financial performance indicate a company on the cusp of significant growth, with a robust 26% revenue CAGR over the past five years, albeit with challenges to overcome. According to InvestingPro 's analysis, Vertex maintains a "Good" financial health score, supported by strong liquidity and moderate debt levels. ...

How has Vertex Pharmaceuticals performed over 3 months?

Positive Revenue Trend: Examining Vertex Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 13.3% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. ...

What does Vertex Pharmaceuticals's market capitalization mean?

Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence. Positive Revenue Trend: Examining Vertex Pharmaceuticals's financials over 3 months reveals a positive narrative. ...

Is Vertex Pharmaceuticals navigating a critical juncture?

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company with a market capitalization of $113.7 billion, is navigating a critical juncture as it seeks to expand its therapeutic reach and maintain its market dominance. ...